News
- Author:
- Will Pass
Publish date: August 27, 2018
MUNICH - Rivaroxaban did not change outcome in patients with heart failure and coronary artery disease in the COMMANDER trial.
News
- Author:
- Will Pass
Publish date: August 26, 2018
The MARINER study looked at postdischarge rivaroxaban in individuals who had been recently hospitalized and were at an increased risk of venous thr...
News
- Author:
- Will Pass
Publish date: August 22, 2018
In a review of five studies of single-dose RT, 89% of patients achieved local control and less than 5% experienced severe toxicity.
News
- Author:
- Will Pass
Publish date: August 22, 2018
Investigators estimate that 85% of patients with metastatic RCC may experience SREs and related complications, with an average of more than two eve...
News
- Author:
- Will Pass
Publish date: August 22, 2018
The nivolumab plus ipilimumab combination was considered most likely to offer clinical benefit for first-line metastatic esophagogastric cancer and...
News
- Author:
- Will Pass
Publish date: August 2, 2018
Increased toxicity was a concern with the addition of the novel agent.
News
- Author:
- Will Pass
Publish date: July 30, 2018
Investigators looked at what achieving seronegativity in the first year of treatment meant for the chances of long-term sustained drug-free remissi...
News
- Author:
- Will Pass
Publish date: July 27, 2018
Although no primary or secondary endpoints were met, avelumab demonstrated similar antitumor activity, compared with chemotherapy.
News
- Author:
- Will Pass
Publish date: July 26, 2018
Rapid EGFR-specific testing in patients with NSCLC reduced median time to initiation (TTI) of therapy from 37 days to 22 days.
News
- Author:
- Will Pass
Publish date: July 25, 2018
Providing thawed plasma on the way to the hospital helped reduce mortality for trauma patients.
News
- Author:
- Will Pass
Publish date: July 24, 2018
New IAS-USA HIV guidelines emphasize earlier treatment and initial three-drug antiretroviral therapy.
News
- Author:
- Will Pass
Publish date: July 12, 2018
Patients with melanoma brain metastases receiving first-line checkpoint blockade immunotherapy had a 91% increase in 4-year survival.
News
- Author:
- Will Pass
Publish date: June 18, 2018
In contrast to previous studies, urban patients reported longer delays in care, scoring “Getting Care Quickly” 2.27 points lower than rural patient...
News
- Author:
- Will Pass
Publish date: June 5, 2018
Overall survival at 12 months in NSCLC patients treated with pembrolizumab-combination therapy was 69.2%, compared with 49.4% in patients treated w...
News
- Author:
- Will Pass
Publish date: May 21, 2018
Flares during checkpoint inhibitor therapy were generally mild, and toxicity rates were only slightly increased in NSCLC patients with AID.
